Anavex life sciences receives rare pediatric disease designation from fda for anavex®2-73 (blarcamesine) for the treatment of rett syndrome

Anavex life sciences corp. announced that it received the rare pediatric disease (rpd) designation from the u.s. food and drug administration (fda) for anavex®2-73 (blarcamesine) for the treatment of rett syndrome, a rare genetic neurological disorder associated with severe physical and cognitive impairments that afflicts mostly girls. the rpd designation provides priority review by the fda to encourage treatments for rare pediatric diseases. under the rpd program, a sponsor who receives an approval for a drug for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive a priority review by the fda of a subsequent marketing application for a different product.
AVXL Ratings Summary
AVXL Quant Ranking